HCA

HCA Healthcare Inc

Add to Watchlist

Advanced Chart

382.910

+1.3(0.341%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

384.820

Open

381.760

VWAP

382.55

Vol

991.57K

Mkt Cap

89.60B

Low

378.540

Amount

379.33M

EV/EBITDA(TTM)

9.38

Total Shares

261.91M

135.99B

EV/OCF(TTM)

11.39

P/S(TTM)

1.32

HCA Healthcare, Inc. is a health care services company. It owns, manages or operates hospitals, ambulatory surgery centers (ASCs), freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, hospices, and various other facilities. Its general, acute care hospitals provide a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. Its behavioral hospitals provide a full range of mental health care services through inpatient, partial hospitalization and outpatient settings. It operates approximately 190 hospitals and 2,400 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

19.12B

+4.38%

7.068

+9.58%

19.50B

+6.66%

7.358

+18.3%

18.55B

+6.07%

5.674

+15.79%

Estimates Revision

The market is revising Upward the revenue expectations for HCA Healthcare, Inc. (HCA) for FY2025, with the revenue forecasts being adjusted by 0.38% over the past three months. During the same period, the stock price has changed by 5.40%.

Revenue Estimates for FY2025

Revise Upward

+0.38%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.39%

In Past 3 Month

Stock Price

Go Up

+5.40%

In Past 3 Month

18 Analyst Rating

1.57% Upside

Wall Street analysts forecast HCA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCA is 388.93 USD with a low forecast of 332.00 USD and a high forecast of 444.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

9 Hold

0 Sell

Moderate Buy

1.57% Upside

Current: 382.910

Low

332.00

Averages

388.93

High

444.00

1.57% Upside

Current: 382.910

Low

332.00

Averages

388.93

High

444.00

Barclays

Overweight

downgrade

$416 -> $390

2025-07-28

Reason

Barclays

Price Target

$416 -> $390

2025-07-28

downgrade

Overweight

Reason

Barclays lowered the firm's price target on HCA Healthcare to $390 from $416 and keeps an Overweight rating on the shares post the Q2 report. The firm says the company's CEO expressed confidence in navigating 2026 and beyond.

Wolfe Research

Justin Lake

Outperform -> Peer Perform

downgrade

2025-07-28

Reason

Wolfe Research

Justin Lake

Price Target

2025-07-28

downgrade

Outperform -> Peer Perform

Reason

Wolfe Research analyst Justin Lake downgraded HCA Healthcare to Peer Perform from Outperform without a price target. The firm cites the potential for healthcare exchange pressure in 2026 and provider tax pressure in 2028 and beyond for the downgrade. Wolfe now sees a less compelling risk/reward for the shares amid HCA's legislative pressure.

RBC Capital

Ben Hendrix

Outperform

maintain

$404 -> $401

2025-07-28

Reason

RBC Capital

Ben Hendrix

Price Target

$404 -> $401

2025-07-28

maintain

Outperform

Reason

RBC Capital analyst Ben Hendrix lowered the firm's price target on HCA Healthcare to $401 from $404 and keeps an Outperform rating on the shares. Despite the Q2 beat and raise, the firm is not surprised to see HCA shares trade modestly lower after the print given the softer volume outlook and greater-than-expected rate support from supplemental programs, the analyst tells investors in a research note. RBC adds however that it is encouraged by the management's confidence in resiliency efforts and its ability to mitigate Medicaid and exchange provisions of the OBBB.

TD Cowen

Buy

maintain

$361 -> $380

2025-07-28

Reason

TD Cowen

Price Target

$361 -> $380

2025-07-28

maintain

Buy

Reason

TD Cowen raised the firm's price target on HCA Healthcare to $380 from $361 and keeps a Buy rating on the shares. The firm updated its model following its quarterly report and noted management will seize the enahnaced subsidy headwind in Q4 earnigs whxi has now become the focal point and controversy for investors.

Morgan Stanley

Craig Hettenbach

Equal Weight

downgrade

$410 -> $400

2025-07-28

Reason

Morgan Stanley

Craig Hettenbach

Price Target

$410 -> $400

2025-07-28

downgrade

Equal Weight

Reason

Morgan Stanley analyst Craig Hettenbach lowered the firm's price target on HCA Healthcare to $400 from $410 and keeps an Equal Weight rating on the shares. In "a noisy backdrop for hospital stocks," HCA's diversified business, solid track record and aggressive cash returns to shareholders "stand out favorably," though greater clarity on the Health Insurance Exchange marketplace into 2026 is likely needed for multiple expansion, the analyst tells investors.

BofA

Buy

Neutral

downgrade

$410 -> $394

2025-07-16

Reason

BofA

Price Target

$410 -> $394

2025-07-16

downgrade

Buy

Neutral

Reason

BofA downgraded HCA Healthcare to Neutral from Buy with a price target of $394, down from $410.

See All Ratings

Valuation Metrics

The current forward P/E ratio for HCA Healthcare Inc (HCA.N) is 13.91, compared to its 5-year average forward P/E of 13.49. For a more detailed relative valuation and DCF analysis to assess HCA Healthcare Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

13.49

Current PE

13.91

Overvalued PE

15.18

Undervalued PE

11.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

8.78

Current EV/EBITDA

9.00

Overvalued EV/EBITDA

9.57

Undervalued EV/EBITDA

8.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

1.13

Current PS

1.17

Overvalued PS

1.27

Undervalued PS

0.98